Bausch Health Cos Inc. (NYSE:BHC) Receives $7.42 Consensus Price Target from Brokerages

Bausch Health Cos Inc. (NYSE:BHC) has been given an average rating of “Reduce” by the seven brokerages that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating and six have assigned a hold rating to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $7.42.

A number of brokerages have issued reports on BHC. Wall Street Zen lowered Bausch Health Cos from a “buy” rating to a “hold” rating in a research report on Saturday, May 10th. Royal Bank Of Canada boosted their target price on Bausch Health Cos from $8.50 to $10.00 and gave the company a “sector perform” rating in a research report on Friday, May 2nd.

Insider Buying and Selling

In related news, Director John Paulson bought 3,564,059 shares of the company’s stock in a transaction on Friday, June 13th. The stock was bought at an average cost of $5.94 per share, with a total value of $21,170,510.46. Following the completion of the acquisition, the director now owns 32,791,702 shares in the company, valued at approximately $194,782,709.88. This represents a 12.19% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders bought 6,352,667 shares of company stock valued at $35,870,767 over the last ninety days. Corporate insiders own 8.12% of the company’s stock.

Institutional Trading of Bausch Health Cos

Several large investors have recently modified their holdings of BHC. JPMorgan Chase & Co. boosted its position in Bausch Health Cos by 1,246.0% during the fourth quarter. JPMorgan Chase & Co. now owns 19,840 shares of the company’s stock worth $160,000 after acquiring an additional 18,366 shares during the last quarter. Vanguard Group Inc. boosted its position in Bausch Health Cos by 1.3% during the fourth quarter. Vanguard Group Inc. now owns 11,684,859 shares of the company’s stock worth $94,460,000 after acquiring an additional 145,078 shares during the last quarter. Raymond James Financial Inc. acquired a new stake in Bausch Health Cos during the fourth quarter worth approximately $180,000. Two Sigma Investments LP boosted its position in Bausch Health Cos by 688.2% during the fourth quarter. Two Sigma Investments LP now owns 265,461 shares of the company’s stock worth $2,140,000 after acquiring an additional 231,781 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its position in Bausch Health Cos by 1.1% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,284,036 shares of the company’s stock worth $10,375,000 after acquiring an additional 14,558 shares during the last quarter. 78.65% of the stock is currently owned by institutional investors and hedge funds.

Bausch Health Cos Stock Performance

BHC stock opened at $5.73 on Friday. The firm has a market cap of $2.12 billion, a PE ratio of -52.11 and a beta of 0.28. The firm’s 50 day moving average price is $4.88 and its 200-day moving average price is $6.38. Bausch Health Cos has a one year low of $3.96 and a one year high of $9.85.

Bausch Health Cos Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.